O'Keeffe Charles B 4
4 · CATALYST PHARMACEUTICALS, INC. · Filed Feb 17, 2023
Insider Transaction Report
Form 4
O'Keeffe Charles B
Director
Transactions
- Exercise/Conversion
Common Stock, par value $0.001 per share
2023-02-15+4,000→ 620,391 total - Exercise/Conversion
Restricted Stock Units
2023-02-15−4,000→ 260,500 total→ Common Stock (4,000 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
- [F2]Derivative securities vest in equal tranches, 1/3rd on February 14, 2023, 1/3rd on February 14, 2024 and 1/3rd on February 14, 2025.
- [F3]Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on February 15, 2023.